Triple-Negative Breast Cancer (TNBC) Active Not Recruiting Phase 2 Trials for Eribulin (DB08871)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01372579Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsTreatment